Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.14
CLVS's Cash to Debt is ranked lower than
78% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CLVS: 1.14 )
Ranked among companies with meaningful Cash to Debt only.
CLVS' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: No Debt Max: No Debt
Current: 1.14
F-Score: 1
Z-Score: -4.20
M-Score: -5.27
WACC vs ROIC
13.33%
-784.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -178.05
CLVS's ROE (%) is ranked lower than
90% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CLVS: -178.05 )
Ranked among companies with meaningful ROE (%) only.
CLVS' s ROE (%) Range Over the Past 10 Years
Min: -178.05  Med: -55.78 Max: -26.78
Current: -178.05
-178.05
-26.78
ROA (%) -63.85
CLVS's ROA (%) is ranked lower than
75% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CLVS: -63.85 )
Ranked among companies with meaningful ROA (%) only.
CLVS' s ROA (%) Range Over the Past 10 Years
Min: -144.39  Med: -49.23 Max: -21.25
Current: -63.85
-144.39
-21.25
ROC (Joel Greenblatt) (%) -9800.46
CLVS's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CLVS: -9800.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9800.46  Med: -6626.76 Max: -3834.63
Current: -9800.46
-9800.46
-3834.63
EBITDA Growth (3Y)(%) 51.80
CLVS's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CLVS: 51.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.4  Med: -31.4 Max: 51.8
Current: 51.8
-53.4
51.8
EPS Growth (3Y)(%) 48.80
CLVS's EPS Growth (3Y)(%) is ranked higher than
91% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CLVS: 48.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.1  Med: -31.1 Max: 48.8
Current: 48.8
-53.1
48.8
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CLVS Guru Trades in Q4 2015

Paul Tudor Jones 225,000 sh (+5346.62%)
Steven Cohen 117,100 sh (unchged)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
» More
Q1 2016

CLVS Guru Trades in Q1 2016

Kyle Bass 100,000 sh (New)
Jim Simons 515,400 sh (New)
Steven Cohen 603,100 sh (unchged)
Paul Tudor Jones 13,858 sh (-93.84%)
» More
Q2 2016

CLVS Guru Trades in Q2 2016

Kyle Bass Sold Out
Paul Tudor Jones Sold Out
Jim Simons 307,200 sh (-40.40%)
» More
Q3 2016

CLVS Guru Trades in Q3 2016

Louis Moore Bacon 95,000 sh (New)
Columbia Wanger 204,000 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GENSF, NAS:XLRN, NAS:AAAP, NYSE:AXON, NAS:FGEN, NAS:OPHT, NAS:ARRY, NAS:TBPH, NAS:ALDR, NYSE:CBM, NAS:FOLD, NAS:AVXS, NAS:CHRS, NYSE:EBS, OTCPK:MPSYY, NAS:DERM, OTCPK:SXMDF, NAS:HALO, NAS:AMAG, NAS:FPRX » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.

Top Ranked Articles about Clovis Oncology Inc

Kyle Bass Purchases Stake in Clovis Oncology Company has been aiming for FDA approval for its lung cancer drug
During the first quarter guru Kyle Bass (Trades, Portfolio) purchased 100,000 shares of Clovis Oncology Inc. (NASDAQ:CLVS). Read more...

Ratios

vs
industry
vs
history
P/B 25.55
CLVS's P/B is ranked lower than
94% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CLVS: 25.55 )
Ranked among companies with meaningful P/B only.
CLVS' s P/B Range Over the Past 10 Years
Min: 1.28  Med: 3.82 Max: 25.55
Current: 25.55
1.28
25.55
Current Ratio 5.61
CLVS's Current Ratio is ranked higher than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CLVS: 5.61 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 10.74 Max: 31.09
Current: 5.61
0.86
31.09
Quick Ratio 5.61
CLVS's Quick Ratio is ranked higher than
59% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CLVS: 5.61 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 10.74 Max: 31.09
Current: 5.61
0.86
31.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.50
CLVS's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CLVS: -13.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.9 Max: -13.5
Current: -13.5
-194.7
-13.5

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -31.36
CLVS's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CLVS: -31.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -164.27  Med: 0 Max: 0
Current: -31.36
-164.27
0

More Statistics

EPS (TTM) $ -10.41
Beta1.74
Short Percentage of Float31.16%
52-Week Range $11.57 - 40.29
Shares Outstanding (Mil)38.59
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
Kyle Bass Purchases Stake in Clovis Oncology May 25 2016 
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
Here is What Hedge Funds Think About Gener8 Maritime Inc (GNRT) Dec 05 2016
Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc.,... Dec 01 2016
Newman Ferrara LLP Announces Corporate Governance Investigation of Clovis Oncology Inc. Nov 30 2016
Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio? Nov 30 2016
Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Vetr Crowd Doesn't Like Outlook For Clovis Oncology Nov 23 2016
Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According to a Recently Filed... Nov 17 2016
CLOVIS ONCOLOGY, INC. Financials Nov 15 2016
Westmoreland Coal Company (WLB), Corrections Corp Of America (CXW): Here’s Why Traders Are Piling... Nov 09 2016
Clovis (CLVS) Stock Up on Narrower-than-Expected Q3 Loss Nov 07 2016
Clovis 3Q Loss $66 Million or $1.70 a Share (CLVS) Nov 05 2016
CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report Nov 04 2016
Edited Transcript of CLVS earnings conference call or presentation 3-Nov-16 8:30pm GMT Nov 04 2016
Clovis reports 3Q loss Nov 03 2016
Clovis reports 3Q loss Nov 03 2016
Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today Nov 03 2016
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update Nov 03 2016
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)